Синдром Шницлер: на пути к лимфопролиферативному процессу?

1. Muzes G, Sipos F. Background and clinical features of a unique and mysterious autoinflammatory disease, Schnitzler syndrome. Int J Mol Sci. 2025;26(2):598.

PMID: 39859314. PMCID: PMC11765222. https://dx.doi.org/10.3390/ijms26020598

2. Новиков П.И., Колхир П.В., Муравьева Е.А., Моисеев С.В., Олисова О.Ю., Никитин Е.А. с соавт. Хроническая крапивница с моноклональной секрецией иммуноглобулина М (синдром Шницлер): описание двух клинических случаев. Фарматека. 2013;(15):90–96. (Novikov PI, Kolkhir PV, Muravyova EA, Moiseev SV, Olisova OYu, Nikitin EA et al. Chronic urticaria with monoclonal secretion immunoglobulin M (Shnitzler syndrome): Analysis of two clinical cases. Farmateka = Pharmateka. 2013;(15):90–96 (In Russ.)). EDN: RLNXQJ.

3. Chu CQ. Schnitzler syndrome and Schnitzler-like syndromes. Chin Med J. 2022;135(10):1190–202.

PMID: 35089885. PMCID: PMC9337259. https://dx.doi.org/10.1097/CM9.0000000000002015

4. Wesselmann AS, Kunstner A, Fahnrich A, Rose C, Lamprecht P, Busch H et al. Case report: Schnitzler-like syndrome without monoclonal gammopathy. Front Immunol. 2023;14:1166620.

PMID: 37063861. PMCID: PMC10097979. https://dx.doi.org/10.3389/fimmu.2023.1166620

5. Nicolas-Sanchez FJ, Arostegui-Gorospe JI, Tarragona-Foradada J, Gonzalez-Barranquero A. Schnitzler syndrome, and the MEFV gene variant. Actas Dermosifiliogr. 2024;115(7):T744–T745 (In English, Spanish).

PMID: 38815681. https://dx.doi.org/10.1016/j.ad.2024.05.006

6. Krause K, Sabat R, Witte-Handel E, Schulze A, Puhl V, Maurer M, Wolk K. Association of CCL2 with systemic inflammation in Schnitzler syndrome. Br J Dermatol. 2019;180(4):859–68.

PMID: 30339714. https://dx.doi.org/10.1111/bjd.17334

7. Gertz MA. Waldenstrom macroglobulinemia: 2021 update on diagnosis, risk stratification, and management. Am J Hematol. 2021;96(2):258–69.

PMID: 33368476. https://dx.doi.org/10.1002/ajh.26082

8. Minderman M, Lantermans H, van der Zwaan C, Hoogendijk AJ, van den Biggelaar M, Kersten MJ et al. The oncogenic human B-cell lymphoma MYD88 L265P mutation genocopies activation by phosphorylation at the Toll/interleukin-1 receptor (TIR) domain. Blood Cancer J. 2023;13(1):125.

PMID: 37591861. PMCID: PMC10435502. https://dx.doi.org/10.1038/s41408-023-00896-6

9. Pathak S, Rowczenio DM, Owen RG, Doody GM, Newton DJ, Taylor C et al. Exploratory study of MYD88 L265P, rare NLRP3 variants, and clonal hematopoiesis prevalence in patients with Schnitzler syndrome. Arthritis Rheumatol. 2019;71(12):2121–25.

PMID: 31268627. https://dx.doi.org/10.1002/art.41030

10. Mulla E, Neame R. Delayed development of the IgM paraprotein in Shnitzler’s syndrome. Scand J Rheumatol. 2015;44(6):521–22.

PMID: 26395927. https://dx.doi.org/10.3109/03009742.2015.1071421

11. Simon A, Asli B, Braun-Falco M, De Koning H, Fermand JP, Grattan C et al. Schnitzler’s syndrome: Diagnosis, treatment, and follow-up. Allergy. 2013;68(5):562–68.

PMID: 23480774. https://dx.doi.org/10.1111/all.12129

12. Колхир П.В., Муравьева Е.А., Олисова О.Ю., Никитин Е.А., Новиков П.И., Моисеев В.С. c cоавт. Синдром Шницлер. Российский журнал кожных и венерических болезней. 2014;(2):8–13. (Kolkhir PV, Muravyova EA, Olisova OYu, Nikitin EA, Novikov PI, Moiseev VS et al. Schnitzler syndrome. Rossiysky zhurnal kozhnykh i venerichesikh bolezney = Russian Journal of Skin and Veneral Diseases. 2014;(2):8–13 (In Russ.)). EDN: SCBVBV.

13. Салугина С.О., Городецкий В.Р., Федоров Е.С., Лопатина Н.Е., Евсикова М.Д. Синдром Шнитцлера: обзор литературы, собственное наблюдение, опыт лечения ингибитором интерлейкина-1 канакинумабом. Терапевтический архив. 2017;89(11):111–115. (Salugina SO, Gorodetsky VR, Fedorov ES, Lopatina NE, Evsikova MD. Schnitzler syndrome: A review of literature, the autors’observation, and experience with the interleukin-1 inhibitor canakinumab. Terapevticheskiy arkhiv = Therapeutic Archive. 2017;89(11):111–115 (In Russ.)).

EDN: ZWOSSH. https://doi.org/10.17116/terarkh20178911111-115

14. de Koning HD, Bodar EJ, van der Meer JW, Simon A.; Schnitzler Syndrome Study G. Schnitzler syndrome: Beyond the case reports: Review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin Arthritis Rheum. 2007;37(3):137–48.

PMID: 17586002. https://dx.doi.org/10.1016/j.semarthrit.2007.04.001

15. de Koning HD. Schnitzler’s syndrome: Lessons from 281 cases. Clin Transl Allergy. 2014;4:41.

PMID: 25905009. PMCID: PMC4405827. https://dx.doi.org/10.1186/2045-7022-4-41

16. Neel A, Henry B, Barbarot S, Masseau A, Perrin F, Bernier C et al. Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler’s syndrome: A French multicenter study. Autoimmun Rev. 2014;13(10):1035–41.

PMID: 25220180. https://dx.doi.org/10.1016/j.autrev.2014.08.031

17. Adam Z, Tomiska M, Rehak Z, Koukalova R, Krejci M, Kral Z et al. Transformation of IgM-MGUS into Waldenstrom’s macroglobulinemia in two of six patients treated for Schnitzler’s syndrome. Vnitr Lek. 2021;67(E-3):15–23 (In Czech).

PMID: 34171947. https://dx.doi.org/10.36290/vnl.2021.046

18. Sokumbi O, Drage LA, Peters MS. Clinical and histopathologic review of Schnitzler syndrome: The Mayo Clinic experience (19722011). J Am Acad Dermatol. 2012;67(6):1289–95.

PMID: 22627038. https://dx.doi.org/10.1016/j.jaad.2012.04.027

19. Gameiro A, Gouveia M, Pereira M, Tellechea O, Goncalo M. Clinical characterization and long-term follow-up of Schnitzler syndrome. Clin Exp Dermatol. 2016;41(5):461–67.

PMID: 27238847. https://dx.doi.org/10.1111/ced.12828

20. Varettoni M, Arcaini L, Zibellini S, Boveri E, Rattotti S, Riboni R et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom’s macroglobulinemia and related lymphoid neoplasms. Blood. 2013;121(13):2522–28.

PMID: 23355535. https://dx.doi.org/10.1182/blood-2012-09-457101